Overexpression of COX-2 and its clinical significance in non-small cell lung cancer.
- Author:
Feng TIAN
1
;
Tian-you WANG
;
Min GONG
;
Xiao-mei LU
;
Jian HU
;
Jing WANG
;
Chang-huai ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Carcinoma, Non-Small-Cell Lung; enzymology; mortality; pathology; Cyclooxygenase 2; Female; Humans; Immunohistochemistry; Isoenzymes; analysis; Lung Neoplasms; enzymology; mortality; pathology; Male; Membrane Proteins; Middle Aged; Prognosis; Prostaglandin-Endoperoxide Synthases; analysis; Survival Rate
- From: Chinese Journal of Surgery 2003;41(6):407-410
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the relations among COX-2 expression in non-small cell lung cancer (NSCLC), its clinical characteristics and brognosis.
METHODSImmunostaining was performed with COX-2 antibody to the surgically resected tissue samples from 79 patients with NSCLC. Vessel epithelium cell COX-2 expression was taken as positive control.
RESULTSThe positive rate of adenocarcinoma and squamous cell carcinoma was 85% and 57%, respectively (P = 0.013). COX-2 expression was associated with the extent of adenocarcinoma differentiation, tumor size, and TNM period, but not with the extent of squamous cell carcinoma differentiation. In the COX-2 positive group, the 5-year survival rate and a median survival time were 27.1% and 53 months; however in the negative group they were 52.0% and 61 months (P = 0.029).
CONCLUSIONInvasive development of NSCLC is related to inceased expression of COX-2. COX-2 overexpression may be one of the risky factors for the prognosis of NSCLC.
